21,257 results match your criteria Infectious Myositis


Time after time: individuals with multiple fractures and injury recidivists in long eighteenth-century (c. 1666-1837) London.

Authors:
Madeleine Mant

Int J Paleopathol 2018 Sep 20;24:7-18. Epub 2018 Sep 20.

Memorial University of Newfoundland, Department of Archaeology, Queen's College, 210 Prince Philip Drive, St. John's NL A1B 3R6, Canada; McMaster University, Department of Anthropology, Chester New Hall, 1280 Main Street West, Hamilton, ON L8S 4L8, Canada. Electronic address:

Investigating injury recidivism and individuals with multiple injuries is an area of growing interest in bioarchaeology. Differentiating between whether an individual sustained multiple injuries, represented by antemortem healed fractures, in one incident or in multiple incidents over the life course, is a major challenge. This research analyzed the skeletal remains of 721 adults (402 males, 319 females) from five post-medieval cemeteries from London, UK, known to include working class individuals for evidence of skeletal trauma - fractures, myositis ossificans, subluxations/dislocations, blunt force trauma, and sharp force trauma. Read More

View Article
September 2018

Antisynthetase syndrome pathogenesis: knowledge and uncertainties.

Curr Opin Rheumatol 2018 Sep 2. Epub 2018 Sep 2.

Sorbonne Universités, Université Pierre et Marie Curie Université Paris 06, INSERM U1135, CNRS ERL8255, Centre d'Immunologie et des Maladies Infectieuses.

Purpose Of Review: Antisynthetase syndrome (ASyS) is an acquired myopathy characterized by the presence of myositis-specific autoantibodies directed against tRNA-synthetases. ASyS is potentially life threatening due to lung involvement and treatment remains a challenge to date. With symptoms not limited to muscles but also involving lung, skin and joints, ASyS appears specific and has a particular pathogenesis, different from the other inflammatory myopathies. Read More

View Article
September 2018

Peculiar clinicopathological features of immune-mediated necrotizing myopathies.

Curr Opin Rheumatol 2018 Sep 19. Epub 2018 Sep 19.

Sorbonne Universités, AP-HP, Hôpital Pitié Salpêtrière, Département de médecine Interne et Immunologie Clinique, Centre de Référence Maladies Neuro-Musculaires.

Purpose Of Review: In the past decade, immune-mediated necrotizing myopathies have emerged as a separate entity in the heterogenous group of autoimmune myopathies. This group is characterized by clinical manifestations restricted to the muscle tissue, and until recently, the definition was based on muscular pathological features.

Recent Findings: It was shown that they are the most severe autoimmune myopathies in term of muscle damages. Read More

View Article
September 2018

A review on the treatment of sporadic inclusion body myositis with Bimagrumab and Alemtuzumab.

Int J Neurosci 2018 Sep 21:1-16. Epub 2018 Sep 21.

c Third Department of Neurology , G. Papanikolaou General Hospital , Thessaloniki , Greece.

Background: Sporadic inclusion body myositis is the most common inflammatory myopathy over the age of 50. The aetiopathogenesis of the disease remains unclear and to the day there is no effective treatment.

Objectives: The aim of the present review is to present the latest data on the new insights and developments in the treatment of sporadic inclusion body myositis, focusing on Bimagrumab and Alemtuzumab. Read More

View Article
September 2018

New insights in myositis-specific autoantibodies.

Curr Opin Rheumatol 2018 Sep 17. Epub 2018 Sep 17.

Unit of Rheumatology, Department of Medicine, University of Padova, Padova, Italy.

Purpose Of Review: The aim of this study was to provide the most recent evidence on clinical utility of myositis-specific autoantibodies (MSAs) in the management of patients with myositis.

Recent Findings: In the last few years, several evidences have emerged on the clinical and pathogenetic role of established and novel MSA. Antisynthetase antibodies represent a reliable biomarker for pulmonary involvement also in patients with connective tissue diseases other than myositis. Read More

View Article
September 2018

Analysis of autoantibody profiles in two asbestiform fiber exposure cohorts.

J Toxicol Environ Health A 2018 Sep 19:1-13. Epub 2018 Sep 19.

e Cumming School of Medicine , University of Calgary , Calgary , Canada.

An increased risk for Systemic Autoimmune Diseases (SAID) was reported in the population of Libby, Montana, where extensive exposure to asbestiform amphiboles occurred through mining and use of asbestiform fiber-laden vermiculite. High frequencies of antinuclear autoantibodies (ANA) were detected in individuals and mice exposed to Libby Asbestiform Amphiboles (LAA). Among the 6603 individuals who have undergone health screening at the Center for Asbestos Related Diseases (CARD, Libby MT), the frequencies of rheumatoid arthritis, systemic lupus erythematosus, sarcoidosis, and systemic sclerosis are significantly higher than expected prevalence in the United States. Read More

View Article
September 2018

Detection of piscine orthoreoviruses (PRV-1 and PRV-3) in Atlantic salmon and rainbow trout farmed in Germany.

Transbound Emerg Dis 2018 Sep 19. Epub 2018 Sep 19.

Fish Disease Research Unit, Institute for Parasitology, University of Veterinary Medicine, Hannover, Germany.

Piscine orthoreoviruses (PRVs) are emerging pathogens causing circulatory disorders in salmonids. PRV-1 is the etiological cause of heart and skeletal muscle inflammation (HSMI) in farmed Atlantic salmon (Salmo salar), characterized by epicarditis, inflammation and necrosis of the myocardium, myositis and necrosis of red skeletal muscle. In 2017, two German breeding farms for Atlantic salmon and rainbow trout (Oncorhynchus mykiss), respectively, experienced disease outbreaks with mortalities of 10% and 20%. Read More

View Article
September 2018

Disseminated extrapulmonary Legionella pneumophila infection presenting with panniculitis: case report and literature review.

BMC Infect Dis 2018 Sep 17;18(1):467. Epub 2018 Sep 17.

Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, 270 Rama VI Road, Ratchathewi District, Bangkok, Thailand.

Background: Legionellosis is a well-known cause of pneumonia. Primary cutaneous and subcutaneous infection caused by Legionella pneumophila is rare and the diagnosis is challenging.

Case Presentation: A 38-year-old Thai woman with systemic lupus erythematosus and myasthenia gravis treated with prednisolone and azathioprine presented to our hospital with low-grade fever, diarrhea, and indurated skin lesions on both thighs. Read More

View Article
September 2018

Rapid Progression of Heart Failure in a Patient with Idiopathic Inflammatory Myopathy.

Am J Med Case Rep 2018 23;6(8):157-160. Epub 2018 Aug 23.

Divisions of Cardiovascular Disease and Rheumatology, Department of Internal Medicine, State University of New York, Downstate Medical Center, Brooklyn, New York, U.S.A- 11203.

Idiopathic inflammatory myopathy (IIM) is a rare autoimmune myopathy that includes polymyositis, dermatomyositis, inclusion body myositis and autoimmune necrotizing myositis. Cardiac involvement was considered a rare occurrence in IIM however, recent reports suggests that cardiac involvement is a common feature and portends poor prognosis as it is usually encountered in advanced disease. IIM leads to myocarditis with subsequent development of myocardial fibrosis, cardiac conduction system disease and cardiomyopathy resulting in both systolic and diastolic heart failure. Read More

View Article
August 2018
1 Read

Perceptions of Patients, Caregivers, and Healthcare Providers of Idiopathic Inflammatory Myopathies: An International OMERACT Study.

J Rheumatol 2018 Sep 15. Epub 2018 Sep 15.

From the Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA; Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Department of Neurology, Care Science and Society, Division of Physiotherapy, and Department of Medicine, Rheumatology Unit, Karolinska Institutet; Function Area Occupational Therapy and Physical Therapy, Allied Health Professionals Function, Karolinska University Hospital; Department of Learning, Informatics and Medical Education, Karolinska Institutet, Solna, Sweden; Department of Neurology, Fiona Stanley Hospital, IIID Murdoch University and Notre Dame University, Murdoch, Australia; Patient Research Partner, the Netherlands and USA; Division of Rheumatology, Rheumatology Unit, Department of Medicine, Karolinska University, Karolinska Institutet, Solna, Sweden; Center for Global Health, University of Ottawa, Ottawa, Ontario, Canada; Department of Neurology, Academic Medical Center, University of Amsterdam, the Netherlands; Medical Research Center, College of Medicine, Department of Molecular Medicine and Biopharmaceutical Sciences, Seoul National University, Seoul, South Korea. Portions of the work have been supported by the Rheumatic Diseases Research Core Center (P30-AR053503/AR070254) Human Subjects Core from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health (NIH). Dr. Mecoli is a Jerome L. Greene Foundation Scholar and the Foundation has provided support for his work. Dr. Bingham was supported in part through a Methods Award SC14-1402-10818 from the Patient-Centered Outcomes Research Institute (PCORI). Dr. Christopher-Stine is supported through the Huayi and Siuling Zhang Discovery Fund. Portions of the work have been supported by NuFactor and OptionCare. H. Alexanderson and M. Regardt are supported by the Swedish Rheumatism Association. There was funding from OMERACT, which receives unrestricted funds from over 23 clinical research and pharmaceutical companies. All statements in this report including its conclusions are solely those of the authors and do not reflect the opinions of the Patient-Centered Outcomes Research Institute (PCORI), its Board of Governors or Methodology Committee, or of the NIH or NIAMS. C.A. Mecoli, MD, Division of Rheumatology, Department of Medicine, Johns Hopkins University; J.K. Park, MD, Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital; H. Alexanderson, PhD, Physiotherapist, Department of Neurology, Care Science and Society, Division of Physiotherapy, and Department of Medicine, Rheumatology Unit, Karolinska Institutet, and Function Area Occupational Therapy and Physical Therapy, Allied Health Professionals Function, Karolinska University Hospital; M. Regardt, PhD, Occupational Therapist, Department of Learning, Informatics and Medical Education, Karolinska Institutet, and Function Area Occupational Therapy and Physical Therapy, Allied Health Professionals Function, Karolinska University Hospital; M. Needham, MD, Department of Neurology, Fiona Stanley Hospital, IIID Murdoch University and Notre Dame University; I. de Groot, Patient Research Partner, the Netherlands; C. Sarver, Patient Research Partner, USA; I.E. Lundberg, MD, PhD, Division of Rheumatology, Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet; B. Shea, MSN, Center for Global Health, University of Ottawa; M. de Visser, MD, Department of Neurology, Academic Medical Center, University of Amsterdam; Y.W. Song, MD, PhD, Division of Rheumatology, Department of Internal Medicine, Medical Research Center, College of Medicine, Department of Molecular Medicine and Biopharmaceutical Sciences, Seoul National University; C.O. Bingham 3rd, MD, Division of Rheumatology, Department of Medicine, Johns Hopkins University; L. Christopher-Stine, MD, Division of Rheumatology, Department of Medicine, Johns Hopkins University. Dr. Mecoli and Dr. Park are co-first authors. Address correspondence to Dr. C.A. Mecoli, Johns Hopkins University School of Medicine, Division of Rheumatology, 5200 Eastern Ave., MFL Bldg., Center Tower, Suite 4100, Baltimore, Maryland 21224, USA. E-mail: Accepted for publication June 28, 2018.

Objective: Patient-reported outcome measures (PROM) that incorporate the patient perspective have not been well established in idiopathic inflammatory myopathies (IIM). As part of our goal to develop IIM-specific PROM, the Outcome Measures in Rheumatology (OMERACT) Myositis special interest group sought to determine which aspects of disease and its effects are important to patients and healthcare providers (HCP).

Methods: Based on a prior qualitative content analysis of focus groups, an initial list of 24 candidate domains was constructed. Read More

View Article
September 2018
1 Read

Atypical Presentation of Fibrodysplasia Ossificans Progressiva: A Case Report and Review of Literature.

Cureus 2018 Jul 10;10(7):e2955. Epub 2018 Jul 10.

Department of Orthopaedics, All India Institute of Medical Sciences, Bhopal, IND.

Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disease characterized by widespread areas of abnormal bone formation in muscles, ligaments, tendons and joint capsules. Typically, the symptoms begin in the first decade of life with episodes of painful inflammatory soft tissue swellings. Gradually, there occurs restriction of motion at various joints, severely limiting the activities of daily living and the quality of life of such patients by the third decade of life. Read More

View Article
July 2018
1 Read

Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies.

JAMA Neurol 2018 Sep 10. Epub 2018 Sep 10.

Centre de Recherche en Myologie, Unité Mixte de Recherche Scientifique 974, Université Pierre et Marie Curie, Institut National de la Santé et de la Recherche Médicale, Paris, France.

Importance: Idiopathic inflammatory myopathies are heterogeneous in their pathophysiologic features and prognosis. The emergence of myositis-specific autoantibodies suggests that subgroups of patients exist.

Objective: To develop a new classification scheme for idiopathic inflammatory myopathies based on phenotypic, biological, and immunologic criteria. Read More

View Article
September 2018
3 Reads

Author Correction: Treatment in myositis.

Nat Rev Rheumatol 2018 Sep 11. Epub 2018 Sep 11.

Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

In the originally published version of this article, several references in Table 1 were incorrect. These errors have now been corrected in the HTML and PDF versions of the manuscript. Read More

View Article
September 2018
2 Reads

Exercise for Athletes With Inflammatory Arthritis.

Curr Sports Med Rep 2018 Sep;17(9):302-307

Department of Orthopaedics, University of Utah School of Medicine, Salt Lake City, UT.

Advances in pharmacologic management of inflammatory conditions have allowed those living with these conditions to pursue fitness activities previously difficult due to functional limitations. With that said, many patients with inflammatory arthritis are still not active enough. In this article, we review specific exercise recommendations for a number of inflammatory conditions with a focus on overall health promotion and cardiovascular disease risk reduction, discuss exercise as an adjunct to pharmacologic disease management, and review potential risks of sport participation for athletes with inflammatory arthritis conditions. Read More

View Article
September 2018
2 Reads

Myositis Ossificans in Sport: A Review.

Curr Sports Med Rep 2018 Sep;17(9):290-295

Department of Family Medicine, VCU School of Medicine, VCU, Fairfax Family Practice Sports Medicine, Fairfax, VA.

Myositis ossificans is a benign, solitary, frequently self-limiting, ossifying soft-tissue mass encountered often in the active sporting population. Typically occurring within skeletal muscle - most often the brachialis, quadriceps and adductor muscle groups - lesions may arise with or without a traumatic history. The exact pathophysiology of these ossifying lesions is still poorly understood. Read More

View Article
September 2018

Clinical features and outcome of patients with acute respiratory failure revealing anti-synthetase or anti-MDA-5 dermato-pulmonary syndrome: a French multicenter retrospective study.

Ann Intensive Care 2018 Sep 11;8(1):87. Epub 2018 Sep 11.

Service de Réanimation Polyvalente, Centre Hospitalier Victor Dupouy, 69 rue du Lieutenant Colonel Prudhon, 95100, Argenteuil, France.

Background: Anti-synthetase (AS) and dermato-pulmonary associated with anti-MDA-5 antibodies (aMDA-5) syndromes are near one of the other autoimmune inflammatory myopathies potentially responsible for severe acute interstitial lung disease. We undertook a 13-year retrospective multicenter study in 35 French ICUs in order to describe the clinical presentation and the outcome of patients admitted to the ICU for acute respiratory failure (ARF) revealing AS or aMDA-5 syndromes.

Results: From 2005 to 2017, 47 patients (23 males; median age 60 [1st-3rd quartiles 52-69] years, no comorbidity 85%) were admitted to the ICU for ARF revealing AS (n = 28, 60%) or aMDA-5 (n = 19, 40%) syndromes. Read More

View Article
September 2018
1 Read

Periostin expression in neoplastic and non-neoplastic diseases of bone and joint.

Clin Sarcoma Res 2018 5;8:18. Epub 2018 Sep 5.

1Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal and Sciences, Nuffield Orthopaedic Centre, University of Oxford, Oxford, OX3 7HE UK.

Background: Periostin is a matricellular protein that is expressed in bone and joint tissues. To determine the expression of periostin in primary bone tumours and to assess whether it plays a role in tumour progression, we carried out immunohistochemistry and ELISA for periostin in a range of neoplastic and non-neoplastic bone and joint lesions.

Methods: 140 formalin-fixed paraffin-embedded sections of bone tumours and tumour-like lesions were stained by an indirect immunoperoxidase technique with a polyclonal anti-periostin antibody. Read More

View Article
September 2018
2 Reads

Neuro-ophthalmic complications of IgG4-related disease.

Curr Opin Ophthalmol 2018 Sep 7. Epub 2018 Sep 7.

Department of Neuro-Ophthalmology, Massachusetts Eye & Ear Infirmary, Boston, Massachusetts, USA.

Purpose Of Review: IgG4-related disease (IgG4-RD) is increasingly recognized as a fibroinflammatory disease with a plethora of organ-specific manifestations but a particular predilection for head and neck tissues, including the nervous system. This review discusses general features and organ-specific presentations of IgG4-RD as well as treatment considerations, particularly emphasizing features of neuro-ophthalmic interest.

Recent Findings: IgG4-RD is emerging as a common cause of several fibroinflammatory disorders in the head and neck that were previously considered idiopathic, such as sclerosing orbital pseudotumor, orbital myositis, hypophysitis, and hypertrophic pachymeningitis. Read More

View Article
September 2018
3 Reads

Inflammatory myopathies following allogeneic stem cell transplantation.

Muscle Nerve 2018 Sep 8. Epub 2018 Sep 8.

Department of Rheumatology, Royal Adelaide Hospital, Port Road, Adelaide, South Australia 5000, Australia.

Introduction: Graft versus host disease (GVHD) is a recognized complication of allogeneic stem cell transplantation (allo-SCT) and may affect muscle. We investigated the incidence and subtypes of inflammatory myopathy (IM) in South Australian recipients of allo-SCT.

Methods: Recipients of allo-SCT from 2004 - 2014 at the Royal Adelaide Hospital were identified. Read More

View Article
September 2018
2 Reads

PROTON PUMP INHIBITORS ARE NOT ASSOCIATED WITH INFLAMMATORY MYOPATHIES: A CASE CONTROL STUDY.

Muscle Nerve 2018 Sep 7. Epub 2018 Sep 7.

Rheumatology Unit, The Queen Elizabeth Hospital, Australia.

Introduction: A rare association of proton pump inhibitor (PPI) use with the development of inflammatory myopathies (IM) has been reported but unlike with statin medications, there is sparse data supporting or refuting this.

Methods: A case-control study was conducted of patients with IM. Clinical information, medications and demographics were recorded. Read More

View Article
September 2018

Calcified leiomyoma of the deltoid: pathophysiology and imaging review.

Skeletal Radiol 2018 Sep 5. Epub 2018 Sep 5.

University of Texas John P. and Katherine G. McGovern Medical School, 6431 Fannin St., Houston, TX, 77030, USA.

Leiomyomas are benign tumors of smooth muscle cells. Leiomyomas of somatic soft tissue are a specific class of leiomyoma believed to arise from the smooth muscle cells found in the walls of blood vessels and represent less than 4% of benign, somatic soft tissue tumors. Of the somatic soft tissue tumors, approximately one-third will become calcified. Read More

View Article
September 2018
2 Reads

Proposed cut-off for reactivity of anti-HMGCR and anti-SRP antibodies in patients statin-exposed and statin-unexposed.

Medicine (Baltimore) 2018 Aug;97(35):e11858

Clinical Analysis Laboratory.

The therapeutic approach with statins is widely used in the control of dyslipidemias. However, there is no laboratory evaluation to elect patients to make use of this class of therapeutic drugs.We analyzed the prevalence of anti-signal recognition particle (anti-SRP) and anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) antibodies in a heterogeneous cohort of 85 patients in order to determine cutoff reference values for these antibodies. Read More

View Article

Erosive Arthritis Resembling Osteomyelitis in Behcet's Disease.

J Coll Physicians Surg Pak 2018 Sep;28(9):719-720

Korea University College of Medicine, Seoul, Korea.

Erosive arthritis in Behcet's disease (BD) is rare and confused with infectious diseases such as osteomyelitis. Clinical course and imaging may be similar in BD-related arthritis and osteomyelitis. A 48-year woman diagnosed with BD developed recurrent pain in both feet. Read More

View Article
September 2018
1 Read

T-cell transcriptomics from peripheral blood highlights differences between polymyositis and dermatomyositis patients.

Arthritis Res Ther 2018 Aug 29;20(1):188. Epub 2018 Aug 29.

Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

Background: Polymyositis (PM) and dermatomyositis (DM) are two distinct subgroups of idiopathic inflammatory myopathies, a chronic inflammatory disorder clinically characterized by muscle weakness and inflammatory cell infiltrates in muscle tissue. In PM, a major component of inflammatory cell infiltrates is CD8+ T cells, whereas in DM, CD4+ T cells, plasmacytoid dendritic cells, and B cells predominate. In this study, with the aim to differentiate involvement of CD4+ and CD8+ T-cell subpopulations in myositis subgroups, we investigated transcriptomic profiles of T cells from peripheral blood of patients with myositis. Read More

View Article
August 2018
2 Reads

Dermatomyositis etiopathogenesis: a rebel soldier in the muscle.

Curr Opin Rheumatol 2018 Aug 24. Epub 2018 Aug 24.

Muscle Disease Unit, Laboratory of Muscle Stem Cells and Gene Regulation, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda.

Purpose Of Review: The purpose of this article is to review the etiopathogenesis of dermatomyositis, including the predisposing factors, triggers, inflammatory cells, pathways and target antigens associated with dermatomyositis.

Recent Findings: During the last few years, we have made considerable progress in unveiling the etiopathogenesis of dermatomyositis. In the first place, we have defined genes within the major histocompatibility complex locus as the greatest genetic risk factor for the disease. Read More

View Article
August 2018
4 Reads

Muscle disease in scleroderma.

Authors:
Julie J Paik

Curr Opin Rheumatol 2018 Aug 24. Epub 2018 Aug 24.

Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Purpose Of Review: This review discusses the most updated literature of muscle disease in scleroderma in the past year.

Recent Findings: In the past year, two studies have highlighted that fibrosis is a prevalent histopathologic feature in muscle biopsies of patients with scleroderma muscle disease. In addition, microangiopathy was a common co-feature on muscle biopsies. Read More

View Article
August 2018
6 Reads

Hepatitis is the new myositis: immune checkpoint inhibitor-induced myositis.

Melanoma Res 2018 Oct;28(5):484-485

Department of Medicine, Division of Rheumatology.

View Article
October 2018

Docetaxel-Induced Myositis.

J Clin Rheumatol 2018 Aug 24. Epub 2018 Aug 24.

Department of Pathology, Aster Medcity, Kochi, Kerala, India.

View Article
August 2018
1 Read

Feasibility, safety and efficacy of exercise training in immune-mediated necrotising myopathies: a quasi-experimental prospective study.

Clin Exp Rheumatol 2018 Jul 19. Epub 2018 Jul 19.

Division of Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Brazil.

Objectives: To evaluate the feasibility, safety and efficacy of exercise training in patients with immune-mediated necrotising myopathies (IMNM).

Methods: Eight consecutive sedentary patients with IMNM (5 anti-signal recognition particle and 3 anti-hydroxy-methyl-glutaryl coenzyme A reductase) were engaged in this study. Disease status was based on International Myositis Assessment and Clinical Studies Group (IMACS) core set measures. Read More

View Article
July 2018
4 Reads

Extranodal NK/T-cell Lymphoma Mimicking Granulomatous Myositis: A Case Report.

Intern Med 2018 Aug 24. Epub 2018 Aug 24.

Department of Neurology, Tohoku Medical and Pharmaceutical University, Japan.

Extranodal NK/T-cell lymphoma (ENKTL) is an aggressive non-Hodgkin lymphoma that typically develops in the upper aerodigestive tract. We encountered an ENKTL patient who presented with generalized muscle weakness with eyelid swelling, diplopia, and facial edema. A muscle biopsy revealed lymphocytic infiltration without significant atypia; some lymphocytes formed granuloma-like structures. Read More

View Article
August 2018
2 Reads
0.97 Impact Factor

Myositis autoantibody profiles and their clinical associations in Greek patients with inflammatory myopathies.

Clin Rheumatol 2018 Aug 25. Epub 2018 Aug 25.

Institute for Systemic Autoimmune and Neurological Diseases, Athens, Greece.

Myositis-specific (MSAs) or-associated autoantibodies (MAAs) have been linked to particular clinical phenotypes of idiopathic inflammatory myopathies (IIM) and appear to aid diagnosis. The objective of this study was to analyze the prevalence of MSAs and MAAs and their possible clinical associations in Greek IIM patients. This study comprised 95 IIM patients classified based on the 2017 EULAR/ACR classification criteria. Read More

View Article
August 2018
1 Read

STROBE: The correlation of Cyr61, CTGF, and VEGF with polymyositis/dermatomyositis.

Medicine (Baltimore) 2018 Aug;97(34):e11775

Department of Rheumatism and Immunology, Affiliated Hospital of Qinghai University, Xining.

This study aims to explore the roles of cysteine-rich protein 61 (Cyr61/CCN1), connective tissue growth factor (CTGF/CCN2) and vascular endothelial growth factor (VEGF) in the vascular process of polymyositis (PM)/dermatomyositis (DM).Real-time quantitative polymerase chain reaction was used to determine the mRNA expression of Cyr61, CTGF, and VEGF in muscle tissues of initially treated PM/DM patients and controls. Enzyme-linked immunosorbent assay (ELISA) was used to determine the serum levels of Cyr61, CTGF, and VEGF of initially treated PM/DM patients before and after treatment. Read More

View Article
August 2018
2 Reads

Modeling human somite development and fibrodysplasia ossificans progressiva with induced pluripotent stem cells.

Development 2018 08 23;145(16). Epub 2018 Aug 23.

Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto 606-8507, Japan

Somites (SMs) comprise a transient stem cell population that gives rise to multiple cell types, including dermatome (D), myotome (MYO), sclerotome (SCL) and syndetome (SYN) cells. Although several groups have reported induction protocols for MYO and SCL from pluripotent stem cells, no studies have demonstrated the induction of SYN and D from SMs. Here, we report systematic induction of these cells from human induced pluripotent stem cells (iPSCs) under chemically defined conditions. Read More

View Article
August 2018
1 Read

[The clinical significance of myositis-specific antibodies in polymyositis/dermatomyositis associated interstitial lung diseases].

Zhonghua Jie He He Hu Xi Za Zhi 2018 Aug;41(8):616-621

Department of Respiratory Medicine, Drum Tower, Clinical Medical College of Nanjing Medical University, Nanjing 210008, China.

To investigate the profile and clinical significance of myositis-specific antibody spectrum (MSAs) in patients with polymyositis/dermatomyositis-associated interstitial lung disease (PM/DM-ILD). Sera from 74 patients with PM/DM-ILD, 29 patients with SLE and 32 healthy controls were collected and Euroline Autoimmune Inflammatory Myopathies 16 Ag kit was used for detecting MSAs . The clinical data of all patients were collected from medical records. Read More

View Article
August 2018
1 Read

Inclusion Body Myositis: Update on Pathogenesis and Treatment.

Neurotherapeutics 2018 Aug 22. Epub 2018 Aug 22.

Neuromuscular Medicine Division, Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas, 66103, USA.

Inclusion body myositis is the most common acquired myopathy after the age of 50. It is characterized by progressive asymmetric weakness predominantly affecting the quadriceps and/or finger flexors. Loss of ambulation and dysphagia are major complications of the disease. Read More

View Article
August 2018
1 Read

Ophthalmic Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss Syndrome): A Systematic Review of the Literature.

Ophthalmic Plast Reconstr Surg 2018 Aug 21. Epub 2018 Aug 21.

Department of Ophthalmology and Visual Sciences, Montefiore Medical Center, Bronx, New York, U.S.A.

Purpose: To review and summarize the clinical features, presentations, diagnostic modalities, and management of ophthalmic manifestations of eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss Syndrome).

Methods: A systematic PubMed search of all English articles on EGPA with ophthalmic involvement was performed. Emphasis was placed on English-language articles, but any article with an abstract translated into English was also included. Read More

View Article
August 2018
5 Reads

Muscle-dominant wild-type TDP-43 expression induces myopathological changes featuring tubular aggregates and TDP-43-positive inclusions.

Exp Neurol 2018 Nov 18;309:169-180. Epub 2018 Aug 18.

Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan.

Muscle histology of sporadic inclusion body myositis (sIBM) demonstrates inflammatory findings and degenerative features including accumulation of TAR DNA-binding protein of 43 kDa (TDP-43). However, whether sarcoplasmic accumulation of TDP-43 is a primary trigger of muscle degeneration or a secondary event resulting from muscle degeneration in the pathophysiology of sIBM remained unclear. Our study aimed to discover whether muscle-dominant expression of TDP-43 is a primary cause of muscle degeneration. Read More

View Article
November 2018
1 Read

Classification and management of adult inflammatory myopathies.

Lancet Neurol 2018 Sep;17(9):816-828

Muscle Disease Unit, Laboratory of Muscle Stem Cells and Gene Regulation, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Inflammatory myopathies, collectively known as myositis, are heterogeneous disorders characterised by muscle inflammation, and frequently accompanied by extramuscular manifestations that affect the skin, lung, and joints. Patients with inflammatory myopathies were previously classified as having dermatomyositis if characteristic rashes accompanied the muscle involvement, and as having polymyositis if no rashes were present. Five main types of inflammatory myopathies are now widely recognised: dermatomyositis, immune-mediated necrotising myopathy, sporadic inclusion-body myositis, overlap myositis (including antisynthetase syndrome), and polymyositis. Read More

View Article
September 2018
9 Reads

RocA has serotype-specific gene regulatory and pathogenesis activity in serotype M28 group A streptococcus.

Infect Immun 2018 Aug 20. Epub 2018 Aug 20.

Center for Molecular and Translational Human Infectious Diseases Research, Department of Pathology and Genomic Medicine, Houston Methodist Research Institute and Houston Methodist Hospital, Houston, Texas, USA

Serotype M28 group A streptococcus (GAS) is a common cause of infections such as pharyngitis ("strep throat") and necrotizing fasciitis ("flesh-eating" disease). Relatively little is known about the molecular mechanisms underpinning M28 GAS pathogenesis. Whole genome sequencing studies of M28 GAS strains recovered from patients with invasive infections found an unexpectedly high number of missense (amino acid changing) and nonsense (protein truncating) polymorphisms in (egulator f ov), leading us to hypothesize that altered RocA activity contributes to M28 GAS molecular pathogenesis. Read More

View Article
August 2018
1 Read
3.73 Impact Factor

Juvenile dermatomyositis: novel treatment approaches and outcomes.

Curr Opin Rheumatol 2018 Aug 16. Epub 2018 Aug 16.

Paediatric Rheumatology Department, Great Ormond Street Hospital for Children NHS Foundation Trust.

Purpose Of Review: The aim of this article is to provide a summary of the recent therapeutic advances and the latest research on outcome measures for juvenile dermatomyositis (JDM).

Recent Findings: Several new international studies have developed consensus-based guidelines on diagnosis, outcome measures and treatment of JDM to standardize and improve patient care. Myositis-specific antibodies together with muscle biopsy histopathology may help the clinician to predict disease outcome. Read More

View Article
August 2018
4 Reads

Autoimmune Neuromuscular Diseases Induced by Immunomodulating Drugs.

J Clin Neuromuscul Dis 2018 Sep;20(1):28-34

Department of Neurology, Neuromuscular Center, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH.

Immunomodulating drugs are widely used in autoimmune, transplant, and cancer patients. However, these drugs are associated with various autoimmune neuromuscular diseases such as demyelinating polyneuropathy, myasthenia gravis, and myositis. Early recognition of these complications and immediately terminating these drugs are very essential since some are life-threatening conditions. Read More

View Article
September 2018

Idiopathic Orbital Inflammation: Review of Literature and New Advances.

Middle East Afr J Ophthalmol 2018 Apr-Jun;25(2):71-80

Department of Ophthalmology, Ankara University Faculty of Medicine, Ankara, Turkey.

Idiopathic orbital inflammation (IOI) is a benign inflammatory condition usually confined to the orbit but extraorbital extension can also occur. IOI has been classified into categories including anterior, diffuse, posterior or apical, myositis, and dacryoadenitis. Other rare types of IOI include periscleritis, perineuritis, and focal mass. Read More

View Article
September 2018
4 Reads

Autoantibody to transcriptional intermediary factor-1β as myositis-specific antibody: clinical correlation with CADM or DM with mild myopathy.

Br J Dermatol 2018 Aug 18. Epub 2018 Aug 18.

Department of Dermatology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.

Background: Myositis-specific autoantibodies (MSAs) are associated with unique clinical subsets in polymyositis/dermatomyositis (PM/DM). Autoantibodies against transcriptional intermediary factor (TIF)-1γ and TIF-1α are known to be MSAs. Previously, we reported that TIF-1β is also targeted in DM patients with or without concomitant anti-TIF-1α/γ antibodies. Read More

View Article
August 2018
3 Reads

The cooperation of pharmacologic-dose ascorbate with ceftriaxone against Staphylococcus aureus through bactericidal synergy and enhanced macrophage killing activity.

Asian Pac J Allergy Immunol 2018 Aug 13. Epub 2018 Aug 13.

Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

Background: Ascorbate is a low-cost compound with a known bactericidal-synergy to antibitics. However, the synergy depends on concentrations and organisms. Thus, the synergy test by time-kill assay might be appropriate for the screening of the synergy. Read More

View Article
August 2018
2 Reads

Prevalence and clinical correlates of rheumatoid factor and anticitrullinated protein antibodies in patients with idiopathic inflammatory myopathy.

RMD Open 2018 25;4(2):e000661. Epub 2018 Jul 25.

Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium.

Objective: As rheumatoid factor (RF) and anticitrullinated protein antibodies (ACPAs) are not routinely tested in idiopathic inflammatory myositis (IIM), little is known about their prevalence and clinical implications in this patient group. In antisynthetase syndrome (ASS), presence of ACPA is reportedly associated with more severe and erosive arthritis. We aim to retrospectively determine the prevalence of RF and ACPA in a cross-sectional cohort of 121 patients diagnosed with IIM and to assess clinical associations. Read More

View Article
July 2018
1 Read

[Acute respiratory distress revealing antisynthetase syndrome].

Rev Med Liege 2018 Jul;73(7-8):370-375

Service d'Endocrinologie, CHU Sart Tilman, Liège, Belgique.

Antisynthetase syndrome is a clinical entity characterized by specific anti-aminoacyl-tRNA-synthetase antibodies usually associated with inflammatory myopathy and interstitial lung disease. The classic presentation of the pathology is the pulmonary interstitium involvment, wich commonly determines the global prognosis. The subsequent diagnosis of antisynthetase syndrome in patients with acute respiratory distress syndrome (ARDS) is unusual, even more so when a veino-veinous (VV) extracorporeal membrane oxygenation (ECMO) is required. Read More

View Article
July 2018
4 Reads

Dermatomyositis as an extrahepatic manifestation of hepatitis B virus-related hepatocellular carcinoma: A case report and literature review.

Medicine (Baltimore) 2018 Aug;97(33):e11586

Department of Rheumatology, Aerospace Center Hospital, Beijing, PR China.

Rationale: Dermatomyositis is an idiopathic inflammatory myopathy with specific cutaneous manifestations, which is closely associated with malignancy. However, the exact mechanism remains elusive. Even less is known about dermatomyositis with hepatocellular carcinoma (HCC). Read More

View Article
August 2018
5 Reads
5.72 Impact Factor

Clinical signs and symptoms in a joint model of four disease activity parameters in juvenile dermatomyositis: a prospective, longitudinal, multicenter cohort study.

Arthritis Res Ther 2018 Aug 15;20(1):180. Epub 2018 Aug 15.

Paediatric Rheumatology, University College London GOS Institute of Child Health, 30 Guilford Street, London, WC1N 1EH, UK.

Background: It is currently impossible to predict the prognosis of patients with juvenile dermatomyositis (JDM). The aim of this study was to find clinical features most strongly associated with outcome variables in JDM as a first step towards tailor-made treatment.

Methods: In a large, prospectively followed, multicenter cohort study of 340 patients with JDM, each contributing multiple visits, a Bayesian model of disease activity was developed, using the four continuous outcome variables creatine kinase (CK), childhood myositis assessment score (CMAS), manual muscle testing of 8 muscle groups (MMT8) and the physician's global assessment of disease activity (PGA). Read More

View Article
August 2018
3 Reads